Unknown PHASE3 INTERVENTIONAL NCT00336518

Continuing Treatment With Pegasys and Copegus

Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24

Sponsor: Hoffmann-La Roche

Conditions Chronic Hepatitis C

Interventions peginterferon alfa-2a ribavirin

Updated 4 times since 2017 Last updated: Jun 12, 2006 Started: Jun 30, 2006 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00336518, this PHASE3 trial focuses on Chronic Hepatitis C and remains ongoing. Sponsored by Hoffmann-La Roche, it has been updated 4 times since 2006, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE3

First recorded

Jun 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche
Májbetegekért Alapítvány

Data source: Májbetegekért Alapítvány

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Budapest, Hungary